Last updated 2026-07-26
- Raised $25M Series C led by Harel Insurance & Finance, Sep 2025
- Raised $6M grant, Dec 2020
- Raised $8.5M Series A led by Tal Ventures, Oct 2020
Total raised
$43.0M
Last: C Round 2025-10
Stage
Series C
Founded
2015
Headcount
17
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Founded in 2015, the company focuses on innovative anti-infective drugs inspired by the innate immune system of insects, utilizing engineered antimicrobial peptides for therapeutic use. Their technology targets severe hospital-acquired infections (HAI) involving multidrug-resistant (MDR) bacteria, with a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections. The company's lead compound, OMN6, is a first-in-class antimicrobial peptide (AMP) with a novel mechanism of action based on destroying bacterial cell membranes, and it has received Fast-Track and Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA.
Funding history · 4 rounds · $43.0M total
2025-09
C Round
$25.0M
★ Harel Insurance & Finance★ European Innovation CouncilOurCrowdTal VenturesEntrée CapitalPrevail PartnersXenia Venture Capital
2020-12
Grant
$6.0M
2020-10
A Round
$8.5M
★ Tal Ventures★ Entrée CapitalXenia Venture CapitalIsrael Innovation Authority
2018-11
Seed
$3.5M
★ Israel Innovation Authority★ Docor International Management
Headcount over time
From 9 (2019-03) to 26 (2026-03) · +17 (+189%) · 14 points · source: Finder history + radar grounding
Q&A
- What is Omnix Medical's primary focus?
- Omnix Medical is a clinical-stage biopharmaceutical company focused on developing novel antibiotic agents to combat infections caused by drug-resistant bacteria.
- When was Omnix Medical founded?
- Omnix Medical was founded in 2015.
- How many employees does Omnix Medical currently have?
- Omnix Medical has 11-50 employees.
- What is the status of Omnix Medical's lead compound, OMN6?
- OMN6 is a first-in-class antimicrobial peptide (AMP) that has received Fast-Track and Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA. In June 2026, Omnix Medical announced the first patients were dosed in a Phase II trial for OMN6.
- What was Omnix Medical's most recent funding round?
- In October 2025, Omnix Medical completed a C Round, raising $25,000,000. The round was co-led by Harel Insurance & Finance and EIC Fund.
- Which organizations provided grants to Omnix Medical in 2023?
- In October 2023, Omnix Medical received a grant of $11,664,000 from the European Union.
- Who are the co-founders of Omnix Medical?
- The co-founders of Omnix Medical are Dr. Moshik Cohen-Kutner (Co-Founder and CEO), Dr. Niv Bachnoff (Co-Founder and CSO), and Rom Lakritz (Co-Founder and CFO/COO).
- What is the mechanism of action for Omnix Medical's technology?
- Omnix Medical's technology eliminates bacteria by mimicking the innate immune system of insects, using unique molecules to kill resistant bacterial strains efficiently and selectively without toxic effects.
Team · 9
Dr. Moshik Cohen-Kutner
Founder · Co-Founder and CEO
Dr. Niv Bachnoff
Founder · Co-Founder and CSO
Rom Lakritz
Founder · Co-Founder and CFO/COO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
drug-developmentdoctorspeptidesclinical-trialsdrug-discoverypharmaceuticalsantibioticsinfectionpatientsbacteriahospitalsinfectious-disease
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | omnixmedical.com |
|---|---|
| linkedin.com/company/13179766 |
Identifiers & details
| Founded | 2015 |
|---|---|
| Employees (exact) | 17 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | omnixmedical.com |
|---|
Certificate / subdomain footprint
| Subdomains | 11 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515236784 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-03-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 10 — violation (1), annual_report (3), people (2), shares_capital (4) |
| Registered address | פרופ רקח 1 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-29 | עדכון הפרה |
| 2026-06-29 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-06-29 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-06-29 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2026-03-29 | עדכון דירקטורים-הסרת דירקטור |
| 2026-03-29 | עדכון דירקטורים-הוספת דירקטור |
| 2025-12-14 | הקצאת מניות |
| 2025-11-13 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2025-11-09 | הגדלה של הון רשום |
| 2025-12-02 | העברת מניות |